CagriSema is a fixed-dose combination of two peptide drugs developed by Novo Nordisk: cagrilintide (a long-acting amylin analog, C194H312N54O59S2, MW ~4409 Da, 37 amino acids) and semaglutide (a GLP-1 receptor agonist, C187H291N45O59, MW ~4114 Da, 31 amino acids). It is administered as a once-weekly subcutaneous injection.
Undergoing FDA review (not yet approved as of early 2026). Clinical trial dose: cagrilintide 2.4 mg + semaglutide 2.4 mg once weekly via subcutaneous injection. Doses are titrated up gradually over several weeks to minimize GI side effects. Common side effects include nausea, vomiting, diarrhea, and constipation (mostly transient and mild-to-moderate).
Mechanisms of Action
3Benefits
4Superior weight loss
Body CompositionREDEFINE 1 phase 3 trial (3417 adults, 68 weeks): 22.7% mean weight loss with CagriSema vs 15.0% with semaglutide alone, 8.2% with cagrilintide alone, and 2.3% with placebo.
Glycemic control in type 2 diabetes
MetabolicREDEFINE 2 trial demonstrated significant HbA1c reduction and weight loss (13.7% vs 3.4% placebo) in adults with T2D over 68 weeks.
Appetite reduction
MetabolicDual mechanism produces more profound and sustained appetite suppression than GLP-1 agonism alone, leading to reduced caloric intake.
Improved cardiometabolic markers
MetabolicSignificant weight loss is associated with improvements in blood pressure, lipid profiles, and other cardiometabolic risk factors.
Research Studies
3This database is for educational and research purposes only. It is not medical advice. Consult a healthcare professional before using any peptide or supplement.